Entyvio (vedolizumab) is an antibody pharmaceutical. Vedolizumab was first approved as Entyvio on 2014-05-20. It is used to treat crohn disease, enteritis, and ulcerative colitis in the USA. It has been approved in Europe to treat crohn disease and ulcerative colitis. The pharmaceutical is active against integrin alpha-4 and integrin beta-7.
|Indication||crohn disease, enteritis, ulcerative colitis|
|Drug Class||Monoclonal antibodies: humanized, immunomodulating|